- Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells
[作者:Passer, BJ; Castelo-Branco, P; Buhrman, JS; Varghese, S; Rabkin, SD; Martuza, RL,期刊:Cancer gene therapy, 页码:551-560 , 文章类型: Article,,卷期:2009年16-7]
- Genetically engineered oncolytic herpes simplex virus-1 (HSV-1) vectors selectively replicate in tumor cells causing direct killing whereas sparing normal cells. One clinical limitation of using oncolytic HSV vectors is ...
- M-PEIs nanogels: potential nonviral vector for systemic plasmid delivery to tumor cells
[作者:Dong, L; Xu, H; Liu, YB; Lu, B; Xu, DM; Li, BH; Gao, J; Wu, M; Yao, SD; Zhao, J; Guo, YJ,期刊:Cancer gene therapy, 页码:561-566 , 文章类型: Article,,卷期:2009年16-7]
- Successfully systemic gene therapy has been hindered by vector-related limitations, including toxicity and inefficient gene delivery to tumor cells after intravenous administration. In this study, we evaluated the potent...
- NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors
[作者:Rubio-Zapata, HA; Rembao-Bojorquez, JD; Arango-Rodriguez, ML; Dupouy, S; Forgez, P; Martinez-Fong, D,期刊:Cancer gene therapy, 页码:573-584 , 文章类型: Article,,卷期:2009年16-7]
- Neurotensin (NT)-polyplex is a nonviral system for the targeted gene delivery to cells that express and internalize the high-affinity NT receptor (NTSR1). In hemiparkinsonian rats, we previously demonstrated the morpholo...
- Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma
[作者:Kuhlmann, KFD; van Geer, MA; Bakker, CT; Dekker, JEM; Havenga, MJE; Elferink, RPJO; Gouma, DJ; Bosma, PJ; Wesseling, JG,期刊:Cancer gene therapy, 页码:585-597 , 文章类型: Article,,卷期:2009年16-7]
- Survival of patients with pancreatic cancer is poor. Adenoviral (Ad) gene therapy employing the commonly used serotype 5 reveals limited transduction efficiency due to the low amount of coxsackie-adenovirus receptor on p...
- Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients
[作者:Victora, GD; Socorro-Silva, A; Volsi, EC; Abdallah, K; Lima, FD; Smith, RB; Moyses, RA; Zarate-Blades, CR; Michaluart, P; Silva, CL; Kalil, J; Coelho, V,期刊:Cancer gene therapy, 页码:598-608 , 文章类型: Article,,卷期:2009年16-7]
- DNA-hsp65, a DNA vaccine encoding the 65-kDa heat-shock protein of Mycobacterium leprae (Hsp65) is capable of inducing the reduction of established tumors in mouse models. We conducted a phase I clinical trial of DNA-hsp...
|